Microstrategy Inc (MSTR) 172.07 $MSTR MicroStrategy Q3

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Microstrategy Inc (MSTR) 172.07 $MSTR

MicroStrategy Q3 Revenue Retreats
Tim Beyers, The Motley Fool - Motley Fool - Sat Oct 31, 9:35AM CDT
A MicroStrategy dashboard in action. Credit: MicroStrategy.  Days after peer Qlik Technologies ' third-quarter results disappointed investors , shares of MicroStrategy   fell over 10% after hours Monday on declining revenue. Here's a closer...
QLIK: 31.37 (-0.36), MSTR: 172.07 (-2.31)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of MicroStrategy Inc. - MSTR
ACCESSWIRE - Thu Oct 29, 1:27PM CDT
NEW YORK, NY / ACCESSWIRE / October 29, 2015 / Levi & Korsinsky announces it has commenced an investigation of MicroStrategy Inc. (NasdaqGS: MSTR) concerning possible breaches of fiduciary duty by its Board of Directors. To obtain additional information, Go To: http://zlk.9nl.com/microstrategy-mstr or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
MSTR: 172.07 (-2.31)

Why Shares of MicroStrategy Inc. Slumped on Tuesday
Timothy Green, The Motley Fool - Motley Fool - Tue Oct 27, 2:57PM CDT
What: Shares of MicroStrategy slumped on Tuesday following the company's mixed third-quarter earnings report. At 3:30 Tuesday afternoon, the stock was down about 15%. So what: MicroStategy reported quarterly revenue of $129.5 million, down...
MSTR: 172.07 (-2.31)

MicroStrategy Announces Third Quarter 2015 Financial Results
PR Newswire - Mon Oct 26, 3:05PM CDT
MicroStrategy® Incorporated (Nasdaq: MSTR), a leading worldwide provider of enterprise software platforms, today announced financial results for the three-month period ended September 30, 2015 (the third quarter of its 2015 fiscal year).
STZ: 134.80 (-0.31), MSTR: 172.07 (-2.31), STZ.B: 135.12 (-0.55)

Is A Surprise Coming For MicroStrategy (MSTR) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 7:38AM CDT
MicroStrategy (MSTR) seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
MSTR: 172.07 (-2.31)

MicroStrategy Announces Usher(TM) 3.0 Enterprise Security Platform
PR Newswire - Thu Oct 22, 7:00AM CDT
MicroStrategy® Incorporated (Nasdaq: MSTR), a leading worldwide provider of enterprise software platforms, today announced the release of Usher 3.0. Usher is a powerful enterprise security platform that provides advanced security for both logical and physical access, deep identity analytics for business productivity and security, and the ability to locate and communicate with users. Today's release features a new and intuitive badge design that delivers remarkable ease-of-use together with substantial new capabilities.
MSTR: 172.07 (-2.31)

Weiler Corporation Turns Up Efficiencies and Sales Performance with MicroStrategy Analytics(TM)
PR Newswire - Tue Oct 20, 7:00AM CDT
MicroStrategy® Incorporated (Nasdaq: MSTR), a leading worldwide provider of enterprise software platforms, today announced that Weiler Corporation, a global manufacturer based in Cresco, PA, has successfully deployed MicroStrategy Analytics across its business to improve operational efficiencies and sales performance. Weiler Corporation is a world-class industry leader and global manufacturer of surface conditioning solutions.
MSTR: 172.07 (-2.31)

MicroStrategy Announces Earnings Release Date and Conference Call for Third Quarter 2015 Financial Results
PR Newswire - Mon Oct 19, 3:01PM CDT
MicroStrategy® Incorporated (Nasdaq: MSTR), a leading worldwide provider of enterprise software platforms, today announced it will report its financial results for the third quarter of 2015 after the U.S. financial markets close on Monday, October 26, 2015.
MSTR: 172.07 (-2.31)

MicroStrategy Announces Teradata Support for Governed Data Discovery with MicroStrategy 10.1(TM)
PR Newswire - Mon Oct 19, 7:00AM CDT
MicroStrategy® Incorporated (Nasdaq: MSTR), a leading worldwide provider of enterprise software platforms, today announced that its joint customers with Teradata Corporation (NYSE: TDC) will be able to benefit from governed data discovery and sub-second response rates with MicroStrategy 10.1. MicroStrategy is a Diamond Sponsor at Teradata 2015 PARTNERS Conference & Expo taking place this week in Anaheim, CA, where attendees can see a demonstration of MicroStrategy 10.1's capabilities in both a track session on Monday, October 19 at 1:30pm-2:15pm in room 202AB and at MicroStrategy's exhibition booth #207. MicroStrategy business and technical experts will be on hand to showcase MicroStrategy 10.1, which delivers a host of new features and functionality that range from usability upgrades and UX enhancements to further improvements in performance and support for Big Data.
TDC: 28.11 (+0.03), MSTR: 172.07 (-2.31)

Adobe Beats Q3 Earnings & Revenues; Down on Soft Outlook
Zacks Equity Research - Zacks Investment Research - Fri Sep 18, 8:10AM CDT
Adobe Systems Inc. (ADBE) reported third-quarter fiscal 2015 earnings of 39 cents per share, which beat the Zacks Consensus Estimate of 35 cents backed by strong adoption of creative cloud and record Adobe Marketing Cloud revenues.
MANH: 72.85 (-0.11), MSTR: 172.07 (-2.31), ADBE: 88.66 (+0.54)

SAP Launches Hybris to Transform Front-Office Operations
Zacks Equity Research - Zacks Investment Research - Wed Sep 16, 3:10PM CDT
SAP SE (SAP) recently announced that it will launch a portfolio of products based on SAP hybris technology.
SAP: 78.71 (+0.59), IBM: 140.08 (-0.47), MSTR: 172.07 (-2.31), ACN: 107.20 (-0.75)

Microsoft to Reward Shareholders with 16% Dividend Hike
Zacks Equity Research - Zacks Investment Research - Wed Sep 16, 12:30PM CDT
Microsoft Corp. (MSFT) recently announced a huge dividend hike. The company raised its quarterly dividend by 5 cents to 36 cents per share, up 16% from the prior dividend of 31 cents.
MANH: 72.85 (-0.11), MSFT: 52.64 (-0.72), MSTR: 172.07 (-2.31)

MicroStrategy Connector to Presto Opens Door to Fast, Interactive Analytics for Big Data Exploration
PR Newswire - Wed Sep 16, 7:00AM CDT
MicroStrategy® Incorporated (Nasdaq: MSTR), a leading worldwide provider of enterprise software platforms, today announced that through its optimized Presto Connector, MicroStrategy 10 Secure Enterprise(TM) enables organizations with immense amounts of data to run thousands of quick, interactive analytic queries against multiple data stores. Developed by Facebook, Presto is an open source distributed SQL query engine for running interactive analytic queries against data sources of all sizes ranging from gigabytes to petabytes.
MSTR: 172.07 (-2.31)

NetSol Technologies (NTWK) Worth a Look: Stock Up 7.2%
Zacks Equity Research - Zacks Investment Research - Tue Sep 15, 7:30AM CDT
NetSol Technologies, Inc. (NTWK) was a big mover last session, as the company saw its shares rise over 7% on the day.
NTWK: 5.68 (+0.02), MSTR: 172.07 (-2.31)

Microsoft Appoints Smith as President and Chief Legal Officer
Zacks Equity Research - Zacks Investment Research - Mon Sep 14, 12:25PM CDT
Microsoft Corp. (MSFT) recently appointed Brad Smith, an internal executive, as the president and chief legal officer. He will continue to report to the company's CEO, Satya Nadella.
MANH: 72.85 (-0.11), MSFT: 52.64 (-0.72), MSTR: 172.07 (-2.31)

Why Verint Systems (VRNT) Could Be Positioned for a Slump
Zacks Equity Research - Zacks Investment Research - Mon Sep 14, 7:55AM CDT
Verint Systems has an unfavorable Zacks Rank and the stock has been witnessing a significant price decline and negative earnings estimate revisions
VRNT: 47.58 (+0.25), MSTR: 172.07 (-2.31)

Will MicroStrategy (MSTR) Crush Estimates at Its Next Earnings Report?
Zacks Equity Research - Zacks Investment Research - Mon Sep 14, 7:41AM CDT
MicroStrategy has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports
MSTR: 172.07 (-2.31)

MicroStrategy Releases MicroStrategy 10.1
PR Newswire - Tue Sep 08, 7:00AM CDT
MicroStrategy® Incorporated (Nasdaq: MSTR), a leading worldwide provider of enterprise software platforms, today announced the general availability of MicroStrategy 10.1. The release includes hundreds of new and improved features and a wide range of performance enhancements across the product platform. Further extending the self-service capabilities of MicroStrategy 10 Secure Enterprise(TM), MicroStrategy Desktop(TM) 10.1 and MicroStrategy Web(TM) 10.1 add new enhancements for enterprise data discovery users, enabling data preparation and data wrangling across more data sources, while delivering a clean, new look with modern grid styles, navigation, and consolidated views and search. Other highlights include new capabilities for D3 visualizations, ESRI geospatial visualizations, and iOS 9 within MicroStrategy Mobile(TM) and custom Mobile Productivity Apps. To learn more about MicroStrategy Analytics(TM), visit: www.microstrategy.com/analytics.
MSTR: 172.07 (-2.31)

MicroStrategy to Present at Upcoming Citi 2015 Global Technology Conference
PR Newswire - Thu Sep 03, 4:00PM CDT
MicroStrategy® Incorporated (Nasdaq: MSTR), a leading worldwide provider of enterprise software platforms, today announced that it will present at the Citi Global Technology Conference on Thursday, September 10, 2015, at 2:00 p.m. Eastern Daylight Time at the Hilton New York Hotel in New York City.
MSTR: 172.07 (-2.31)

Falling Earnings Estimates Signal Weakness Ahead for Intuit (INTU)
Zacks Equity Research - Zacks Investment Research - Thu Sep 03, 7:51AM CDT
Intuit has an unfavorable Zacks Rank and the stock has been witnessing a significant price decline and negative earnings estimate revisions
MSTR: 172.07 (-2.31), INTU: 97.43 (-0.32)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 79

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 421

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Updated Category News Views 72

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 140

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 93

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 149

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 312

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 87

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading

Top 5 Most Recently Viewed Articles

Kohl's Stock Plummets Amid Retail Challenges and Restructuring

Updated Category News Views 589

Kohl's Corporation Faces Significant Challenges Kohl's Corporation (NYSE: KSS) has recently seen its stock plummet to a concerning 52-week low of $13.61. This decline paints a grim picture of the current retail environment, where shifting consumer habits and fierce competition play a pivotal role. Priced at just 0.4 times book value and boasting a generous 14.5% dividend...

Continue Reading
Rapid Micro Biosystems Achieves Record Growth and Future Outlook

Updated Category News Views 136

Financial Performance Highlights for Rapid Micro Biosystems Rapid Micro Biosystems, Inc. (NASDAQ: RPID) has announced impressive results for the fourth quarter and the entire fiscal year of 2024. The company recorded a total revenue of $8.2 million in the fourth quarter, marking a 30% increase compared to the same period in 2023. Likewise, the full year revenue reached...

Continue Reading
ALZpath and Siemens Team Up for Advanced Alzheimer's Testing

Updated Category News Views 265

ALZpath and Siemens Healthineers Form Strategic Partnership ALZpath is thrilled to announce a significant licensing agreement with Siemens Healthineers. This collaboration marks a pivotal enhancement in the accessibility of diagnostic testing for Alzheimer's disease. The agreement involves the use of ALZpath's proprietary pTau217 antibody, a remarkable tool for...

Continue Reading
Generate:Biomedicines Showcases Promising Results for GB-0895

Updated Category News Views 495

Results from Phase 1 Trials of GB-0895 Unveiled Generate:Biomedicines is making notable headlines with its innovative drug GB-0895. This cutting-edge treatment is an ultra-high affinity anti-TSLP monoclonal antibody, specifically designed for individuals grappling with asthma. With a unique formulation, GB-0895 offers a prolonged half-life and sustained pharmacological...

Continue Reading
Driving Growth in Natural Stone Market and Its Future

Updated Category News Views 226

Steady Growth in the Natural Stone Market The natural stone market is on a promising upward trajectory, predicted to rise from USD 37.89 billion to USD 47.63 billion by a future date, indicating a compound annual growth rate (CAGR) of 4.68%. Various factors are driving this growth, most notably the intense infrastructure investment blooming worldwide. The construction...

Continue Reading